Company intelligence / Profile preview

Medicure Inc.

Winnipeg, Manitoba, Canadamedicure.com ↗

Ownership: Private
Employees: ~38
Development stage: Phase 3

Overview

Medicure has commercial products AGGRASTAT (tirofiban hydrochloride) and ZYPITAMAG (pitavastatin). The company is also in Phase 3 clinical trials for MC-1 for the treatment of seizures associated with PNPO deficiency, which has received Fast Track designation, Rare Pediatric Disease Designation, and Orphan Drug Designation from the FDA.

Therapeutic areas: Rare DiseasesCardiovascular
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

3 assets

Tardoxal

2 more assets in the full pipeline.

Request access →

Partnerships

Zydus Cadila (for ZYPITAMAG)

Beyond the preview

Go deeper on Medicure Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medicure Inc..

Explore the full profile